MarketCapExport financials
NovaBay Pharmaceuticals (NBY)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
NovaBay Pharmaceuticals Income Statement 2025-2002 | NBY
Brief overview of financial performance at NovaBay Pharmaceuticals
The overview follows changes across a five-year period. NovaBay Pharmaceuticals reported revenue of 6.6 million dollars in 2019 and 9.8 million dollars by 2024. The cumulative result was +48.2%, corresponding to roughly 8.2% per year. Sales increased steadily, although without strong acceleration.
The gross result shifted from $4.9 million to $6.5 million, or +33.3%. Costs absorbed a larger share of revenue over the period. Gross profit as a share of revenue changed from 73.7% to 66.3%. Weakening gross profitability reduces the quality of the top-line trend.
EBITDA was −$9.3 million at the beginning and −$7.3 million at the end of the period (+21.4%). Operating performance weakened relative to revenue. EBITDA margin was −141.5% at the start and −75% at the end. The increased EBITDA share is a positive sign.
Net income moved from −$9.7 million at the start to −$7.2 million at the end. The loss narrowed, although sustainable profitability has not yet returned.
Overall conclusion
The results present an uneven picture without one dominant signal. The positive side is supported by higher operating efficiency, net-income growth and revenue expansion. The main areas of concern are pressure from direct costs and a low EBITDA margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement NovaBay Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
7.1 M | 387 K | 16.8 K | 2.48 M | 474 K | 35.6 M | 13.2 M | 32.3 M | 56.7 M | 36.2 M | 7.18 M | 31.8 M | 43.5 M | 38 M | 36.1 M | 8.47 T | - | - | - |
Shares |
5.82 M | 679 K | 120 K | 1.61 M | 1.25 M | 40 M | 21.6 M | 16.9 M | 15.3 M | 9.41 M | 2.78 M | 1.99 M | 1.53 M | 1.18 M | 1.03 M | 23.3 M | - | - | - |
Historical Prices |
1.22 | 0.57 | 0.14 | 1.54 | 0.38 | 0.7 | 0.64 | 0.77 | 3.85 | 3.3 | 2.02 | 15.8 | 30.8 | 28.2 | 33.5 | 363 K | 364 K | 345 K | 3.73 M |
Net Income |
-631 M | -7.22 M | -9.64 M | -10.6 M | -5.82 M | -11 M | -9.66 M | -6.54 M | -7.4 M | -13.2 M | -19 M | -15.2 M | -16 M | -7.03 M | -5.08 M | -4.31 M | 2.7 M | -23.9 M | - |
Revenue |
- | 9.78 M | 10.5 M | 14.4 M | 10.2 M | 9.93 M | 6.6 M | 12.5 M | 18.2 M | 11.9 M | 4.38 M | 1.05 M | 3.48 M | 6.95 M | 11 M | 9.75 M | 15.7 M | - | - |
Cost of Revenue |
- | 3.3 M | 4.37 M | 6.62 M | 3.69 M | 3.97 M | 1.74 M | 1.5 M | 2.78 M | 2.46 M | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 6.48 M | 6.08 M | 7.78 M | 6.52 M | 5.96 M | 4.86 M | 11 M | 15.4 M | 9.43 M | 3.12 M | 568 K | 3.32 M | - | 11 M | - | - | - | - |
Operating Income |
-8.44 M | -7.38 M | -4.1 M | -14.4 M | -8.86 M | -6.43 M | -9.4 M | -7.87 M | -7.31 M | -11 M | -21.1 M | -16.9 M | -15.5 M | -8.31 M | -4.32 M | -4.52 M | 2.74 M | - | - |
Interest Expense |
-20 K | -581 K | -369 K | -276 K | -1.58 M | 605 K | -1.42 M | 19 K | 12 K | -68 K | 17 K | 48 K | 1 K | -155 K | -30 K | 258 K | -36 K | - | - |
EBITDA |
-8.44 M | -7.34 M | -4.05 M | -14.3 M | -8.8 M | -6.38 M | -9.34 M | -7.6 M | -7.22 M | -10.9 M | -20.8 M | -16.6 M | -15.2 M | -7.97 M | -3.9 M | -4.09 M | 3.11 M | - | - |
Operating Expenses |
8.44 M | 7.38 M | 10.2 M | 22.2 M | 15.4 M | 12.4 M | 14.3 M | 18.9 M | 22.8 M | 20.4 M | 24.1 M | 17.4 M | 18.8 M | 15.3 M | 15.3 M | 14.3 M | 12.9 M | - | - |
General and Administrative Expenses |
7.58 M | 7.38 M | 5.45 M | 7.49 M | 7.24 M | 5.93 M | 5.31 M | 5.83 M | 8.64 M | 7.24 M | 18.1 M | 7.94 M | 6.34 M | 5.98 M | 5.43 M | 5.65 M | 5.61 M | - | - |
All numbers in USD currency
Quarterly Income Statement NovaBay Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
31 M | 26 M | 5.88 M | 5.82 M | 5.31 M | 4.88 M | 1.16 M | 1.16 M | 120 K | 321 K | 134 K | 91 K | 2.04 M | 2.04 M | 1.6 M | 1.51 M | 1.43 M | 47.8 M | 44.9 M | 42.6 M | 41.8 M | 41.8 M | 40 M | 30.4 M | 28 M | 27.9 M | 23.1 M | 18.6 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 16.4 M | 15.4 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 10.9 M | 7.41 M | 4.09 M | 3.49 M | 2.96 B | 2.65 B | 2.18 M | 2.07 M | 50.8 M | 50.8 M | 45.3 M | 44.6 M | 37.5 M | 37.3 M | 36.8 M | 36.9 M | 28.9 M | 28.7 M | 28.6 M | 28.6 M | 27.9 M | 23.5 M | 23.6 M |
Net Income |
-41.1 M | 552 M | -1.29 M | -1.92 M | 7.67 M | - | -1.21 M | -1.58 M | -3.21 M | - | -1.76 M | -2.04 M | -1.74 M | - | -136 K | -2.16 M | -111 K | - | -2.29 M | -1.86 M | -1.52 M | - | -3.22 M | -4.48 M | -1.58 M | - | -282 K | -2.5 M | -4.19 M | - | -1.54 M | -1.59 M | -2.15 M | - | -2.45 M | -1.74 M | -4.01 M | - | -3.74 M | -2.69 M | -5.08 M | - | -5.24 M | -4.89 M | -4.64 M | - | -4.22 M | -2.94 M | -3.56 M | - | -3.85 M | -4.05 M | -59.9 M | - | 80 K | -2.23 M | -2.53 M | - | 106 K | 425 K | -1.99 M |
Revenue |
2.21 M | 2.46 M | 521 K | - | - | - | 2.44 M | 2.4 M | 2.63 M | - | 2.48 M | 3.53 M | 2.34 M | - | 3.83 M | 3.66 M | 3.27 M | - | 2.26 M | 2.13 M | 1.81 M | - | 2.17 M | 3.98 M | 1.89 M | - | 1.62 M | 1.79 M | 1.49 M | - | 3.14 M | 2.79 M | 2.95 M | - | 4.09 M | 4.12 M | 3.7 M | - | 3.44 M | 2.66 M | 1.72 M | - | 1.2 M | 1.01 M | 538 K | - | 152 K | 123 K | 100 K | - | 1.1 M | 831 K | 957 K | - | 3.64 M | 871 K | 1.32 M | - | 2.77 M | 4.53 M | 2.49 M |
Cost of Revenue |
- | - | 479 K | - | - | - | 848 K | 808 K | 837 K | - | 819 K | 1.8 M | 739 K | - | 1.45 M | 1.82 M | 1.46 M | - | 712 K | 614 K | 455 K | - | 536 K | 2.04 M | 581 K | - | 401 K | 403 K | 341 K | - | 332 K | 479 K | 251 K | - | 521 K | 698 K | 588 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | 42 K | - | - | - | 1.59 M | 1.59 M | 1.79 M | - | 1.66 M | 1.74 M | 1.6 M | - | 2.38 M | 1.84 M | 1.81 M | - | 1.55 M | 1.52 M | 1.35 M | - | 1.63 M | 1.94 M | 1.31 M | - | 1.21 M | 1.39 M | 1.15 M | - | 2.81 M | 2.32 M | 2.7 M | - | 3.57 M | 3.42 M | 3.11 M | - | 2.87 M | 2.18 M | 1.11 M | - | 931 K | 755 K | 390 K | - | 110 K | 105 K | 58 K | - | -44 K | 1 K | 41 K | - | - | - | - | - | - | - | - |
Operating Income |
-53.8 M | 22.3 M | -1.26 M | -1.89 M | -3.29 M | - | -1.7 M | -1.62 M | -2.29 M | - | -698 K | -1.05 M | -1.34 M | - | -457 K | -2.15 M | -2.38 M | - | -2.29 M | -1.86 M | -1.52 M | - | -2.06 M | -1.07 M | -1.54 M | - | -1.71 M | -1.38 M | -4.07 M | - | -1.81 M | -2.08 M | -2.37 M | - | -2.17 M | -1.76 M | -3.78 M | - | -2.06 M | -2.24 M | -4.65 M | - | -5.35 M | -4.86 M | -4.66 M | - | -4.11 M | -3.79 M | -4.08 M | - | -2.98 M | -4.15 M | -3.49 M | - | -106 K | -2.88 M | -2.48 M | - | -348 K | 440 K | -1.94 M |
Interest Expense |
- | -1.42 M | -77 K | -73 K | -40 K | - | - | -69 K | -460 K | - | -641 K | -432 K | -5 K | - | -171 K | -3 K | -4 K | - | - | 2 K | 2 K | - | 429 K | 362 K | -186 K | - | -719 K | -387 K | -60 K | - | 4 K | 5 K | 4 K | - | 3 K | 4 K | 2 K | - | -4 K | -24 K | -41 K | - | -31 K | -22 K | -11 K | - | -2 K | 57 K | -7 K | - | 3 K | 5 K | - | - | -17 K | 27 K | -5 K | - | 6 K | -11 K | -31 K |
EBITDA |
-53.8 M | 22.3 M | -1.26 M | -1.89 M | -3.29 M | - | -1.7 M | -1.61 M | -2.28 M | - | -685 K | -1.04 M | -1.33 M | - | -428 K | -2.12 M | -2.35 M | - | -2.28 M | -1.85 M | -1.51 M | - | -2.05 M | -1.06 M | -1.52 M | - | -1.7 M | -1.36 M | -4.05 M | - | -1.72 M | -2 M | -2.33 M | - | -2.15 M | -1.74 M | -3.76 M | - | -2.03 M | -2.21 M | -4.61 M | - | -5.31 M | -4.78 M | -4.62 M | - | -3.93 M | -3.64 M | -4.01 M | - | -2.74 M | -3.99 M | -833 K | - | 150 K | -2.7 M | -2.39 M | - | -27 K | 656 K | -1.84 M |
Operating Expenses |
5.42 M | 2.85 M | 1.3 M | 1.89 M | 3.29 M | - | 1.7 M | 1.62 M | 2.29 M | - | 2.36 M | 2.79 M | 2.94 M | - | 2.83 M | 3.99 M | 4.2 M | - | 3.84 M | 3.38 M | 2.87 M | - | 3.7 M | 3.02 M | 2.85 M | - | 2.93 M | 2.76 M | 5.22 M | - | 4.62 M | 4.4 M | 5.06 M | - | 5.74 M | 5.18 M | 6.89 M | - | 4.93 M | 4.42 M | 5.76 M | - | 6.28 M | 5.61 M | 5.05 M | - | 4.22 M | 3.89 M | 4.24 M | - | 4.04 M | 4.98 M | 4.48 M | - | 3.75 M | 3.75 M | 3.8 M | - | 3.12 M | 4.09 M | 4.44 M |
General and Administrative Expenses |
5.42 M | 2.85 M | 1.21 M | 1.89 M | 2.7 M | - | 1.7 M | 1.62 M | 2.29 M | - | 1.09 M | 1.59 M | 1.7 M | - | 956 K | 1.91 M | 2.18 M | - | 1.77 M | 1.57 M | 1.19 M | - | 1.88 M | 1.48 M | 1.28 M | - | 1.33 M | 1.2 M | 1.6 M | - | 1.34 M | 1.36 M | 1.62 M | - | 2.31 M | 1.74 M | 3.09 M | - | 2.27 M | 1.29 M | 1.68 M | - | 1.68 M | 1.95 M | 1.55 M | - | 1.91 M | 1.65 M | 1.71 M | - | 1.52 M | 2.04 M | 1.56 M | - | 1.23 M | 1.37 M | 1.54 M | - | 1.1 M | 1.32 M | 1.52 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company NovaBay Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Schweiz
USA
Israel
China
Canada
Britain
Russia
